Impact pronostic du diabète sucré chez les patients traités par angioplastie coronaire urgente

Anis Ghariani 1, Hamza Mosrati 2, Mohamed Aymen Ben Abdessalem 3, Hatem Bouraoui 1, Ahmed Fekih Romdhane 3, Fares Ammar 1, Abdallah Mahdhaoui 1, Gouider Jeridi 1

1. Service de Cardiologie, CHU Farhat Hached / Faculté de médecine de Sousse
2. Service de Cardiologie, CHU Farhat Hached / Faculté de médecine de Monastir
3. Research laboratory LR14ES05 of cardio-pulmonary system interactions, Ibn El Jazzar Research laboratory LR14ES05 of cardio-pulmonary system interactions, Ibn El Jazzar Medical, Faculty of Sousse. Tunisia.

ABSTRACT

Introduction: Diabetes Mellitus (DM) is known to be associated with worse outcomes following percutaneous coronary intervention (PCI).

Aim: To assess prognostic impact of DM on patients managed by urgent PCI following ST-segment elevation myocardial infarction (STEMI).

Methods: In a retrospective study, STEMI patients admitted to our department from January 2016 to December 2019 and treated with urgent PCI (primary or rescue PCI) were included. They were divided in two groups: Diabetic and non-diabetic patients. They were followed-up for a period of 12 months. Major cardiac adverse event (MACE) was a composite outcome of the following events: myocardial infarction, target vessel revascularization, target lesion revascularization or cardiovascular death. MACEs were collected during follow-up.

Results: Our population consisted of 225 patients. DM was observed in 104 STEMI patients (46.2%). Diabetic patients had higher frequency of hypertension (p<0.001), low-density lipoprotein cholesterol levels > 1.4mmol/l (p<0.001) and chronic kidney disease (CKD) (p=0.009). In-hospital and 12-months mortality were significantly higher in the diabetic group (11.5% versus 4.1%; p=0.036) and (24.7% versus 8.7%; p=0.003). In-hospital and 12-months MACEs were also more frequent among diabetic patients (17.3% versus 6.7%; p=0.013) and (43.5% versus 17.5%; p<0.001). Main factors associated with in-hospital mortality among diabetic patients were age > 75 years, anemia, CKD, cardiogenic shock and procedural failure. Age > 75 years, hyperglycemia at admission (>10mmol/l), extensive anterior infarction and procedure failure were associated with in-hospital mortality in the non-diabetic group. Factors associated with 12-months mortality and MACEs among diabetic patients were age > 75 years, anemia, CKD and left ventricular systolic dysfunction.

Conclusions: Despite modern era of STEMI treatment, diabetic patients still have a poor prognosis. These results highlight the need for coronary risk factors treatment among these patients.

Key words: STEMI, Outcomes, Mortality, Major adverse cardiac event.
INTRODUCTION

Coronary artery disease is a major public health problem. It is the leading cause of death in the world (1). It is also the leading cause of death in Tunisia in 2014 according to World Health Organisation (WHO). ST-segment elevation myocardial infarction (STEMI) requires a rapid diagnosis and immediate revascularization to prevent complications. Diabetes mellitus (DM) is a major cardiovascular risk factor. Compared to the general population, diabetic patients have a more complex coronary anatomy, have more co-morbidities, and are at higher risk of developing complications following percutaneous coronary intervention (PCI) such as stent thrombosis and intracoronary stent restenosis (2). Diabetic patients who develop STEMI, compared to non-diabetic patients present to the emergency department with longer ischemia time, have more hemodynamic instability and frequently get later revascularization (3). This may explain the worse prognosis associated with DM. National registries of STEMI among diabetic patients are lacking. Furthermore, few studies about this issue have been published in Tunisia. The aim of our study was to assess prognostic impact of DM on patients managed by urgent PCI following STEMI.

METHODS

It was an observational, monocentric, retrospective study. From January 2016 to December 2019, patients presenting via emergency medical system with STEMI and treated in the cardiology department of Farhat Hached university hospital center with urgent PCI (primary PCI or rescue PCI) were included. STEMI patients with successful reperfusion after fibrinolytic therapy and STEMI patients who presented after resolution of chest pain (typically more than 24 hours from chest pain onset) were not included. Patients with medical files missing data were excluded. All patients received pre-treatment with aspirin and P2Y12 inhibitors. Anticoagulation with unfractionated heparin was administered following the local protocol (70 IU/kg i.v.). Ethical approval was obtained from the hospital local committee. All patients provided written informed consent before inclusion. Patients were divided in two groups: Diabetic group and non-diabetic group.

Baseline characteristics were collected from medical files. They included: age, sex, DM, hypertension, active smoking (or stopped for less than 3 years) and past medical history including previous myocardial infarction, previous stroke or transient ischemic attack, as well as a known chronic kidney disease (CKD) defined as a glomerular filtration rate < 60ml/min according to modification of diet in renal disease (MDRD) equation. Biological variables were analyzed at admission. They included hemoglobin, serum creatinine, blood glucose and low-density lipoprotein (LDL) cholesterol. Anemia was defined as a hemoglobin level < 12g/dl in women and <13g/dl in men. The considered cut-off for LDL-cholesterol was 1.4mmol/l. Hyperglycemia at admission was defined as blood glucose level > 10mmol/l. Extensive anterior infarction was defined as ST-segment elevation in all precordial leads (V1 through V6). DI and AVL. Patients were hemodynamically evaluated before admission to catheterization laboratory. Cardiogenic shock was defined as “Systolic blood pressure < 90 mmHg and signs of hypoperfusion (cool clammy skin, oliguria or altered sensorium), nonresponsive to fluid resuscitation or pressors” (4).

For primary PCI, symptoms-to-first medical contact and door-to-balloon delays were analyzed. For rescue PCI, symptoms-to-fibrinolytic therapy and fibrinolytic therapy failure-to-balloon delays were analyzed.

Procedural aspects were specified. They included type of PCI (primary or rescue PCI), access route, infarct related artery, type of stents used (drug-eluting stents (DES) or bare-metal stents (BMS)), pre-procedural and post-procedural thrombolysis in myocardial infarction (TIMI) flow, thromboaspiration use and Gp IIb-IIIa inhibitors use. All DES used were second generation (Sirolimus-eluting stents or Everolimus-eluting stents). Procedure failure was defined as the absence of post-procedural TIMI flow 3.

Echocardiography was performed to all patients 24 hours after PCI. Left ventricular systolic dysfunction was defined as left ventricular ejection fraction less than 40%.

Major adverse cardiac event (MACE) was a composite outcome defined as the occurrence of myocardial infarction, target vessel revascularization, target lesion revascularization or cardiovascular death. MACEs and mortality were recorded during the hospital stay and for the next 12 months.

For statistical analysis, categorical data were presented as counts and proportions (%). Continuous data were presented as median or mean ± standard deviation, as appropriate. Differences between groups were evaluated using the Student t tests for continuous data. Chi-squared or Fisher exact tests (if the expected cell value was under 5) were used for categorical variables. Factors associated with mortality and MACEs were identified by univariate and multivariate logistic regression analysis. Odds ratio (OR) and confidence intervals at 95% (95% CI) were calculated. All probability values were two sided and considered statistically significant if p<0.05.

RESULTS

Baseline characteristics

Our population included 225 STEMI patients. Diabetic patients represented 46.2% (104). Baseline characteristics are represented in table 1. Hypertension, CKD, anemia and high LDL-cholesterol levels were more frequent in the diabetic group. However, smoking and hyperglycemia at admission were more frequent in the non-diabetic group.
Table 1. Baseline characteristics in the population study and according to diabetes mellitus

| Variables                      | Population study (n=225) | Diabetic group (n=104) | Non-Diabetic group (n=121) | P value |
|-------------------------------|--------------------------|------------------------|----------------------------|---------|
| Age, mean ± SD (years)        | 61.1 ± 11.8              | 62.4 ± 11              | 59.9 ± 12.3                | NS      |
| Age > 75 years                | 39 (17.3 %)              | 19 (18.3 %)            | 20 (16.5 %)                | NS      |
| Sex, male (%)                 | 167 (74.2 %)             | 73 (70.2 %)            | 94 (77.7 %)                | NS      |
| Hypertension (%)              | 78 (34.8 %)              | 50 (48.1 %)            | 28 (23.1 %)                | <0.001  |
| Active smoking (or stopped for less than three years) (%) | 149 (66.2 %) | 56 (53.8 %) | 93 (76.9 %) | <0.001 |
| High LDL-cholesterol (> 1.4 mmol/l) (%) | 88 (39.1 %) | 56 (53.8 %) | 32 (26.4 %) | <0.001 |
| Anemia* (%)                   | 55 (24.4 %)              | 36 (34.6 %)            | 19 (15.7 %)                | 0.004   |
| Hyperglycemia (> 10 mmol/l) (%) | 77 (34.2 %) | 73 (70.2 %) | 4 (3.3 %) | <0.001 |

CKD: chronic kidney disease defined as a glomerular filtration rate < 60ml/min according to modification of diet in renal disease (MDRD) equation.; LDL-cholesterol: low-density lipoprotein cholesterol; MI: Myocardial infarction; NS: not significant (p value >0.05); SD: standard deviation; TIA: Transient Ischemic attack.

*Anemia is defined as a hemoglobin level < 12g/dl in women and <13g/dl in men.

** Left ventricular systolic dysfunction is defined as left ventricular ejection fraction less than 40%.

Reperfusion delays

For primary PCI, symptoms-to-first medical contact mean delay was 8.66 ± 6.75 hours and door-to-balloon mean delay was 1.5 ± 1.14 hours. These delays were similar in both the diabetic group and the non-diabetic group. (9.2 ± 6.95 hours vs. 8.2 ± 6.60 hours; p=0.405 and 1.44 ± 1.14 hours; p=0.51 respectively).

For rescue PCI, symptoms-to-fibrinolytic therapy mean delay was 5.07 ± 3.75 hours and fibrinolytic therapy failure-to-balloon mean delay was 5.79 ± 4.54 hours. Similarly, there was no difference in these mean delays between diabetic and non-diabetic patients (5.27 ± 3.31 hours vs. 4.90 ± 4.12 hours; p=0.675 and 5.91 ± 3.82 hours vs. 5.70 ± 5.1 hours; p=0.846 respectively).

Procedural aspects

Procedural aspects in the population study and according to DM are summarized in Table 2. There was no difference between diabetic and non-diabetic patients except for DES use which was more frequently implanted in the diabetic group (33.7 % vs. 14.9 %; p=0.002).

Table 2. Procedural aspects in the population study and according to diabetes mellitus

| Variables                      | Population study (n=225) | Diabetic group (n=104) | Non-Diabetic group (n=121) | P value |
|-------------------------------|--------------------------|------------------------|----------------------------|---------|
| Type of PCI                   |                          |                        |                            |         |
| Primary PCI (%)               | 149 (66.2 %)             | 68 (65.4 %)            | 81 (66.9 %)                | NS      |
| Rescue PCI (%)                | 76 (33.8 %)              | 36 (34.6 %)            | 40 (33.1 %)                |         |
| Access route                  |                          |                        |                            |         |
| Trans-radial access route (%) | 148 (65.8 %)             | 73 (70.2 %)            | 75 (62 %)                  | NS      |
| Trans-femoral access route (%)| 77 (34.2 %)              | 31 (29.8 %)            | 46 (38 %)                  |         |
| Pre-procedural TIMI flow (%)  |                          |                        |                            |         |
| 0-1                           | 118 (52.4 %)             | 51 (49 %)              | 67 (55.4 %)                | NS      |
| 2                             | 58 (25.8 %)              | 27 (26 %)              | 31 (25.6 %)                | NS      |
| 3                             | 49 (21.8 %)              | 26 (25 %)              | 23 (19 %)                  | NS      |
| Procedural failure (%)        | 37 (16.4 %)              | 20 (19.2 %)            | 17 (14 %)                  | NS      |
| DES* (%)                      | 53 (23.6 %)              | 35 (33.7 %)            | 18 (14.9 %)                | 0.002   |
| Thrombo-aspiration use (%)    | 34 (15.1 %)              | 12 (11.5 %)            | 22 (18.3 %)                | NS      |
| Glycoprotein Ib-IIIa inhibitors use (%) | 45 (25 %) | 18 (17.3 %) | 27 (22.3 %) | NS      |

DES: Drug-eluting stent; LAD: Left anterior descending artery; LCX: Left circumflex artery; LM: Left Main; NS: not significant (p value >0.05); PCI: percutaneous coronary intervention; RCA: right coronary artery; * All DES used were second generation (Sirolimus-eluting stents or Everolimus-eluting stents)

Infarct-related artery

In-hospital and 12-months outcomes

Table 3 summarizes outcomes of the population study and according to DM. In-hospital and 12-months mortality and MACEs were higher in the diabetic group compared to the non-diabetic group.
Table 3. In-hospital and 12-months outcomes according to diabetes mellitus

| Outcomes               | Population study (n=225) | Diabetic group (n=104) | Non-diabetic group (n=121) | P value |
|------------------------|--------------------------|------------------------|---------------------------|---------|
| **In-hospital outcomes** |                          |                        |                           |         |
| Mortality (%)          | 17 (7.6 %)               | 12 (11.5 %)            | 5 (4.1 %)                 | 0.036   |
| MACEs (%)              | 26 (11.6 %)              | 18 (17.3 %)            | 8 (6.6 %)                 | 0.013   |
| **12-months outcomes**  |                          |                        |                           |         |
| Mortality (%)          | 35 (15.6 %)              | 25 (24.1 %)            | 10 (8.3 %)                | 0.003   |
| MACEs (%)              | 66 (29.3 %)              | 45 (43.5 %)            | 21 (17.4 %)               | <0.001  |

MACEs: major adverse cardiac events

Main predictors of worse outcomes according to diabetes mellitus

- Factors associated with in-hospital mortality
  
  Factors associated with in-hospital mortality and identified by univariate analysis are summarized in table 4. Age > 75 years and procedural failure were associated with in-hospital mortality in both the diabetic and the non-diabetic group. Anemia, CKD and cardiogenic shock were predictors of mortality among diabetic patients only. Extensive anterior infarction and hyperglycemia at admission were associated with in-hospital mortality in the non-diabetic group. Independent factors associated with in-hospital mortality and identified by multivariate logistic regression in the diabetic group were CKD [OR 6.22; 95% CI 1.24 – 31.07; p=0.026], cardiogenic shock [OR 6.82; 95% CI 1.16 – 40.13; p=0.034] and procedure failure [OR 6.23; 95% CI 1.67 – 40.5; p=0.0]. Only extensive anterior infarct was independently associated with in-hospital mortality in the non-diabetic group [OR 6.2; 95% CI 6.12 – 34.27; p<0.001] (Table 5).

- Factors associated with 12-months mortality and MACEs
  
  Factors associated with 12-months mortality among patients with DM, as demonstrated in table 6, were age > 75 years, anemia, CKD and left ventricular systolic dysfunction. These same factors were also associated with 12-months MACEs and none of them was considered statistically significant to predict worse outcomes in the non-diabetic group. Independent factors associated with 12-months mortality among diabetic patients identified by multivariate logistic regression were CKD [OR 9.32; 95% CI 2.13 – 40.93; p=0.003] and left ventricular systolic dysfunction [OR 4.88; 95% CI 1.1 – 21.65; p<0.001]. Anemia and left ventricular systolic dysfunction were independent predictors of 12-months MACEs in the diabetic group: [OR 9.11; 95% CI 2 – 41.46; p=0.004] and [OR 4.06; 95% CI 1 – 16.82; p<0.048] respectively.

Table 4. Factors associated with in-hospital mortality according to diabetes mellitus (univariate analysis).

|                          | Diabetic group | Non-diabetic group | P value |
|--------------------------|----------------|--------------------|---------|
| Age > 75 years           | 31.5 vs. 7     | 0.008              | 15 vs. 2 | 0.031 |
| Anemia*                  | 22.8 vs. 4.7   | 0.006              | 10 vs. 3.3 | 0.22 |
| CKD                      | 33.3 vs. 3.9   | <0.001             | 8.3 vs. 2.9 | 0.363 |
| Cardiogenic shock        | 50 vs. 6.5     | <0.001             | 0 vs. 4.5 | 1 |
| Procedure failure        | 35 vs. 5.9     | 0.002              | 17.6 vs. 1.9 | 0.02 |
| Hyperglycemia (10mmol/l) | 13.7 vs. 10    | 1                  | 75 vs. 2   | <0.001 |

CKD: chronic kidney disease defined as a glomerular filtration rate < 60ml/min according to modification of diet in renal disease (MDRD) equation.

*Anemia is defined as a hemoglobin level < 12g/dl in women and <13g/dl in men.

Table 5. Independent factors associated with worse outcomes (multivariate logistic regression analysis).

|                          | Odds ratio | Confidence interval at 95 % | P value |
|--------------------------|------------|-----------------------------|---------|
| **Independent factors associated with in-hospital mortality in the diabetic group** |           |                             |         |
| CKD                      | 6.22       | 1.24 – 31.07                | 0.026   |
| Cardiogenic shock        | 6.82       | 1.16 – 40.13                | 0.034   |
| Procedure failure        | 6.23       | 1.67 – 40.5                 | 0.01    |
| **Independent factors associated with in-hospital mortality in the non-diabetic group** |           |                             |         |
| Extensive anterior infarct| 6.2        | 6.12 – 34.27                | <0.001  |

Independent factors associated with 12-months mortality in the diabetic group

|                          | Odds ratio | Confidence interval at 95 % | P value |
|--------------------------|------------|-----------------------------|---------|
| CKD                      | 9.32       | 2.13 – 40.93                | 0.003   |
| Left ventricular systolic dysfunction* | 4.88 | 1.1 – 21.65 | <0.001 |

Independent factors associated with 12-months MACEs in the diabetic group

|                          | Odds ratio | Confidence interval at 95 % | P value |
|--------------------------|------------|-----------------------------|---------|
| Anemia**                 | 9.11       | 2 – 41.46                   | 0.004   |
| Left ventricular systolic dysfunction* | 4.06 | 1 – 16.82 | 0.048 |

CKD: chronic kidney disease defined as a glomerular filtration rate < 60ml/min according to modification of diet in renal disease (MDRD) equation; MACEs: major adverse cardiac events.

* Left ventricular systolic dysfunction is defined as left ventricular ejection fraction less than 40%.

**Anemia is defined as a hemoglobin level < 12g/dl in women and <13g/dl in men.
DISCUSSION

The main finding of our study was that DM is associated with higher rates of mortality and MACEs compared to non-diabetic patients. Many studies have reported similar findings (5,6). It has been demonstrated that hyperglycemia at admission (stress hyperglycemia) is associated with larger infarct size and higher mortality in STEMI patients (7). Stress hyperglycemia is most probably induced by the acute release of catecholamine, cytokines and cortisol in the acute stage of MI, but the mechanisms have not been fully elucidated (8). Marfella et al. reported increased intercellular adhesion molecule-1 levels (9) which could augment plugging of leucocytes in the capillaries (10). DM is also associated with higher rates of intracoronary stent restenosis (ISR) (11). Several possible factors can accelerate many of the pathophysiological processes that lead to the higher restenosis rate in the diabetic patients, and mainly because of the alternation of endothelial cell function. Wei-Wen Chan described the peroxisome proliferator activated receptors that are effective in reducing plaque inflammation by inhibiting expression of adhesion molecules and formation of cytokines (12). The elevation and reduction of the aforementioned factors in patients with DM compared with patients without DM cause the following processes: pro-inflammatory state, pro-thrombotic state, accelerated and unstable plaque formation and hemodynamic changes caused by narrowing of vessel diameter, thereby leading to restenosis and plaque formation.

Noman et al. have also reported higher rates of intra-stent complications among diabetic patients (7). Actually, resistance to clopidogrel has been described among diabetic patients. Several factors may explain why diabetics more commonly have an impaired response to clopidogrel compared to non-diabetics. These include insulin resistance, poor glycemic control, and increased inflammatory status (7). Platelets from diabetic patients are poorly responsive to insulin, show an increased response to adenosine diphosphate, and have heightened activity on contact with collagen (13). Moreover, diabetic patients with poor glycemic control have increased platelet reactivity despite dual antiplatelet therapy (14). Ang et al. recently showed that increased plasma fibrinogen is significantly associated with a lower response to clopidogrel in patients with DM, possibly due to a direct interaction of fibrinogen with the glycoprotein IIb/IIIa receptor (15). Furthermore, in diabetic patients increased production of platelet agonists, such as epinephrine and thrombin receptor agonist peptide, may explain the higher levels of platelet activation through different signaling pathways besides those depending on the P2Y12 receptor (16). Thus, in patients with DM a global hyper-reactive platelet status is present, which may explain low responsiveness even after higher maintenance doses of antiplatelet drugs (17). All these factors may explain higher mortality and MACEs in the diabetic group as shown in our study.

Limitations of our study

It was a retrospective study. Some data were lacking. Moreover, the number of patients was limited compared to large published studies, thus, CI were quite large. Further prospective studies should be conducted to offer more information and allow better analysis of DM impact on patients managed by urgent PCI.

REFERENCES

1. Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH. Modifiable Risk Factors in Young Adults With First Myocardial Infarction. J Am Coll Cardiol. 2019;73:573–84.
2. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73:629–38.

3. Foussas SG. Acute coronary syndromes and diabetes mellitus. Hell J Cardiol. 2016;57:375–7.

4. Barron H V., Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the national registry of myocardial infarction 2. Am Heart J 2001;141:933–9.

5. Jiang YJ, Han WX, Gao C, Feng J, Chen ZF, Zhang J, et al. Comparison of clinical outcomes after drug-eluting stent implantation in diabetic versus nondiabetic patients in China. Med (United States). 2017;96:1–8.

6. Chen WW, Chen JY, Li CI, Liu CS, Lin WY, Lin CH, et al. Diabetes mellitus associated with an increased risk of percutaneous coronary intervention long-term adverse outcomes in Taiwan: A nationwide population-based cohort study. J Diabetes Complications. 2020;34:1076–89.

7. Noman A, Balasubramaniam K, Alhous MHA, Lee K, Jesudason P, Rashid M, et al. Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. Catheter Cardiovasc Interv. 2017;89:1195–204.

8. Khalfallah M, Abdelmageed R, Elgendy E, Hafez YM. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Diabetes Vasc Dis Res. 2020;17:1541–9.

9. Marfella R, Esposito K, Giunta R. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000;101:2247-52.

10. Booth G, Stalker TJ, Lefer AM, Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab. 2001;280:848-56.

11. Elezi S, Kastrati A, Pache J. Diabetes mellitus and the clinical and the angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866-73.

12. Capodanno D. Risk stratification for percutaneous coronary intervention. Interv Cardiol Clin 2016;5:249-57.

13. Ferreira IA, Mocking AI, Feigje MA, Gorter G, van Haeften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26:417–22.

14. Singla A, Antonino MJ, Bilden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009;158:784-5.

15. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008;52:1052–59.

16. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541–7.

17. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115:708–16.